REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Stack Library

Anti-Anxiety Stack

Cognitive Enhancementbeginner

81

synergy

81
Share
Peptides

2

Avg Daily mcg

700

Level

beginner

Added

May 17, 2026

Overview

The Anti-Anxiety Stack pairs the anxiolytic peptide Selank with Delta Sleep-Inducing Peptide (DSIP) to address both daytime anxiety and the sleep disruption that typically accompanies chronic stress. Selank''s anxiolytic mechanism operates primarily through allosteric modulation of GABA-A receptors — similar to benzodiazepines but without binding to the benzodiazepine site itself. This produces anxiolysis without sedation, cognitive impairment, tolerance development, or physical dependence. Additionally, Selank stabilizes enkephalin levels in the blood (endogenous opioid peptides that modulate mood and pain), preventing the rapid enzymatic degradation that occurs under chronic stress conditions. DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood during induced sleep. It modulates sleep architecture by promoting delta-wave (slow-wave) sleep — the deepest restorative phase that is typically disrupted by anxiety and chronic stress. DSIP also normalizes cortisol rhythms (reducing elevated evening cortisol that prevents sleep onset) and modulates GABA and serotonin systems. Clinical studies in humans have demonstrated improved sleep quality and reduced time to sleep onset without the hangover effects of pharmacological sleep aids. The combination addresses the anxiety-insomnia cycle from both ends: Selank during the day reduces the stress accumulation and rumination that disrupts evening wind-down, while DSIP at night restores restorative sleep that is essential for next-day stress resilience. Adequate deep sleep is required for emotional memory processing and HPA axis recovery — without it, anxiety compounds daily. This stack breaks that cycle through gentle, non-addictive peptide mechanisms that support rather than override natural neurotransmitter function. The beginner classification reflects the clean side-effect profiles of both compounds and their non-addictive nature.

Dosing Protocol

Selank

Twice per day· nasal

Read more about Selank →

300 mcg

per dose

DSIP

nightly· subcutaneous

Read more about DSIP →

100 mcg

per dose

Goals & Evidence

Anxiety reductionStressCalmSleep onsetMood
Evidence tier:Human RCT

Warnings

  • Selank approved in Russia for anxiety. DSIP (Delta Sleep-Inducing Peptide) has limited but promising human data. Neither FDA-approved in US.

Comments

Sign in to join the discussion

Disclaimer: This stack is community-submitted and for research purposes only. Peptide Contacts does not verify the safety or efficacy of submitted stacks. Always consult a qualified healthcare professional before using any peptide protocol.